BMO Capital Markets said Biogen Inc BIIB shares should trade higher, despite a recent drug trial miss, on CTAD data (Clinical Trials on Alzheimer's Disease).
The CTAD data show:
However, the brokerage maintains its Market Perform rating on Biogen shares, with a price target of $331.
To Go More Bullish
“In order to get more constructive on BIIB, on Friday, we want to see data regarding: (1) ARIA-E severity in titration cohort; (2) 24- month efficacy magnitude; and (3) cognitive benefit from placebo patients switching to aducanumab in LTE,” analyst Ian Somaiya wrote in a note.
Earlier in Friday's morning session, hares of Biogen rose 5.13 percent to $304.39; however, at last check, shares were up just 0.94 percent at $292.25.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.